35 related articles for article (PubMed ID: 26684261)
1. Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women.
Hussain SK; Hessol NA; Levine AM; Breen EC; Anastos K; Cohen M; D'Souza G; Gustafson DR; Silver S; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2084-93. PubMed ID: 24045923
[TBL] [Abstract][Full Text] [Related]
2. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.
De Roos AJ; Mirick DK; Edlefsen KL; LaCroix AZ; Kopecky KJ; Madeleine MM; Magpantay L; Martínez-Maza O
Cancer Res; 2012 Sep; 72(18):4733-43. PubMed ID: 22846913
[TBL] [Abstract][Full Text] [Related]
3. Association between anthropometry and lifestyle factors and risk of B-cell lymphoma: An exposome-wide analysis.
Saberi Hosnijeh F; Casabonne D; Nieters A; Solans M; Naudin S; Ferrari P; Mckay JD; Benavente Y; Weiderpass E; Freisling H; Severi G; Boutron Ruault MC; Besson C; Agnoli C; Masala G; Sacerdote C; Tumino R; Huerta JM; Amiano P; Rodriguez-Barranco M; Bonet C; Barricarte A; Christakoudi S; Knuppel A; Bueno-de-Mesquita B; Schulze MB; Kaaks R; Canzian F; Späth F; Jerkeman M; Rylander C; Tjønneland A; Olsen A; Borch KB; Vermeulen R
Int J Cancer; 2021 May; 148(9):2115-2128. PubMed ID: 33128820
[TBL] [Abstract][Full Text] [Related]
4. Principal components derived from CSF inflammatory profiles predict outcome in survivors after severe traumatic brain injury.
Kumar RG; Rubin JE; Berger RP; Kochanek PM; Wagner AK
Brain Behav Immun; 2016 Mar; 53():183-193. PubMed ID: 26705843
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes.
Levin LI; Ramirez CM; Liao EL; Guo H; Kim BK; Marrogi AJ; Magpantay LI; Breen EC; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2023 Feb; 32(2):233-241. PubMed ID: 36409490
[TBL] [Abstract][Full Text] [Related]
6. Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction.
Landeira-Viñuela A; Arias-Hidalgo C; Juanes-Velasco P; Alcoceba M; Navarro-Bailón A; Pedreira CE; Lecrevisse Q; Díaz-Muñoz L; Sánchez-Santos JM; Hernández ÁP; García-Vaquero ML; Góngora R; De Las Rivas J; González M; Orfao A; Fuentes M
Front Immunol; 2022; 13():965905. PubMed ID: 36248816
[TBL] [Abstract][Full Text] [Related]
7. Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.
Rhee J; Birmann BM; De Roos AJ; Epstein MM; Martinez-Maza O; Breen EC; Magpantay LI; Levin LI; Visvanathan K; Hosgood HD; Rohan TE; Smoller SW; Bassig BA; Qi L; Shu XO; Koh WP; Zheng W; Yuan JM; Weinstein SJ; Albanes D; Lan Q; Rothman N; Purdue MP
Int J Cancer; 2023 Mar; 152(5):865-878. PubMed ID: 36151863
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Molecular Properties of Human Immunodeficiency Virus-Related Diffuse Large B-Cell Lymphoma.
de Carvalho PS; Leal FE; Soares MA
Front Oncol; 2021; 11():675353. PubMed ID: 33996608
[TBL] [Abstract][Full Text] [Related]
9. Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development.
Saberi Hosnijeh F; Kolijn PM; Casabonne D; Nieters A; Solans M; Naudin S; Ferrari P; Mckay JD; Weiderpass E; Perduca V; Besson C; Mancini FR; Masala G; Krogh V; Ricceri F; Huerta JM; Petrova D; Sala N; Trichopoulou A; Karakatsani A; La Vecchia C; Kaaks R; Canzian F; Aune D; Boeing H; Schulze MB; Perez-Cornago A; Langerak AW; van der Velden VHJ; Vermeulen R
Sci Rep; 2020 Aug; 10(1):13814. PubMed ID: 32796953
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of Follicular Lymphoma.
Cerhan JR
Hematol Oncol Clin North Am; 2020 Aug; 34(4):631-646. PubMed ID: 32586570
[TBL] [Abstract][Full Text] [Related]
11. Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes.
Purdue MP; Lan Q; Langseth H; Grimsrud TK; Hildesheim A; Rothman N
Int J Cancer; 2020 Jun; 146(12):3312-3319. PubMed ID: 31523805
[TBL] [Abstract][Full Text] [Related]
12. Markers of Immune Activation and Inflammation, and Non-Hodgkin Lymphoma: A Meta-Analysis of Prospective Studies.
Makgoeng SB; Bolanos RS; Jeon CY; Weiss RE; Arah OA; Breen EC; Martínez-Maza O; Hussain SK
JNCI Cancer Spectr; 2018 Dec; 2(4):pky082. PubMed ID: 30873511
[TBL] [Abstract][Full Text] [Related]
13. Circulating sCD27 and sCD30 in pre-diagnostic samples collected fifteen years apart and future non-Hodgkin lymphoma risk.
Purdue MP; Lan Q; Hoffman-Bolton J; Hildesheim A; Callahan CL; Strickland P; Visvanathan K; Rothman N
Int J Cancer; 2019 Apr; 144(8):1780-1785. PubMed ID: 30230539
[TBL] [Abstract][Full Text] [Related]
14. Obesity and renal cell carcinoma risk by histologic subtype: A nested case-control study and meta-analysis.
Callahan CL; Hofmann JN; Corley DA; Zhao WK; Shuch B; Chow WH; Purdue MP
Cancer Epidemiol; 2018 Oct; 56():31-37. PubMed ID: 30029068
[TBL] [Abstract][Full Text] [Related]
15. Evolving DNA methylation and gene expression markers of B-cell chronic lymphocytic leukemia are present in pre-diagnostic blood samples more than 10 years prior to diagnosis.
Georgiadis P; Liampa I; Hebels DG; Krauskopf J; Chatziioannou A; Valavanis I; de Kok TMCM; Kleinjans JCS; Bergdahl IA; Melin B; Spaeth F; Palli D; Vermeulen RCH; Vlaanderen J; Chadeau-Hyam M; Vineis P; Kyrtopoulos SA;
BMC Genomics; 2017 Sep; 18(1):728. PubMed ID: 28903739
[TBL] [Abstract][Full Text] [Related]
16. Comparison of hematological alterations and markers of B-cell activation in workers exposed to benzene, formaldehyde and trichloroethylene.
Bassig BA; Zhang L; Vermeulen R; Tang X; Li G; Hu W; Guo W; Purdue MP; Yin S; Rappaport SM; Shen M; Ji Z; Qiu C; Ge Y; Hosgood HD; Reiss B; Wu B; Xie Y; Li L; Yue F; Freeman LE; Blair A; Hayes RB; Huang H; Smith MT; Rothman N; Lan Q
Carcinogenesis; 2016 Jul; 37(7):692-700. PubMed ID: 27207665
[TBL] [Abstract][Full Text] [Related]
17. Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses.
Hosnijeh FS; Portengen L; Späth F; Bergdahl IA; Melin B; Mattiello A; Masala G; Sacerdote C; Naccarati A; Krogh V; Tumino R; Chadeau-Hyam M; Vineis P; Vermeulen R
Int J Cancer; 2016 May; 138(10):2357-67. PubMed ID: 26684261
[TBL] [Abstract][Full Text] [Related]
18. Circulating soluble CD30 and future risk of lymphoma; evidence from two prospective studies in the general population.
Vermeulen R; Hosnijeh FS; Portengen L; Krogh V; Palli D; Panico S; Tumino R; Sacredote C; Purdue M; Lan Q; Rothman N; Vineis P
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1925-7. PubMed ID: 21784955
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
